Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

Several other equities research analysts have also issued reports on the stock. Canaccord Genuity Group restated a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Cantor Fitzgerald reissued an overweight rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Piper Sandler assumed coverage on shares of Taysha Gene Therapies in a research report on Tuesday. They set an overweight rating and a $9.00 target price on the stock. Chardan Capital lifted their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a buy rating in a research note on Thursday, March 21st. Finally, JMP Securities restated a market outperform rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of Buy and an average price target of $6.88.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock traded up $0.08 during midday trading on Thursday, reaching $3.22. 2,508,469 shares of the company traded hands, compared to its average volume of 2,727,352. The firm has a market capitalization of $602.20 million, a price-to-earnings ratio of -4.81 and a beta of 0.29. The business has a 50 day moving average of $2.41 and a two-hundred day moving average of $2.11. Taysha Gene Therapies has a 12 month low of $0.50 and a 12 month high of $3.89. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $4.75 million. As a group, research analysts predict that Taysha Gene Therapies will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds have recently added to or reduced their stakes in TSHA. Howard Capital Management Inc. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Victory Capital Management Inc. acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth $28,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Taysha Gene Therapies during the 4th quarter worth $31,000. Capital Investment Advisors LLC purchased a new stake in Taysha Gene Therapies during the 3rd quarter worth about $32,000. Finally, Maven Securities LTD purchased a new stake in Taysha Gene Therapies during the 4th quarter worth about $34,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.